Search Results

Aptose Biosciences Inc. announced the voting results from the Company’s annual and special meeting of shareholders held today, June 18, 2024.

Aptose Biosciences Inc. announced a clinical poster presentation and a preclinical e-poster at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain.

Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced financial results for the first quarter ended March 31, 2024.

Aptose Biosciences Inc. today announced that it has entered into a definitive agreement for the issuance and sale of 3,855,000 of its common shares (or common share equivalents in lieu thereof) at a purchase price of $1.15 per share.

Aptose Biosciences Inc. announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 3,855,000 of its common shares at a purchase price of $1.15 per share.

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months and year ended December 31, 2023, and provided a corporate update.

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 14, 2024, after the close of the market, and provide a corporate update.